Pre-Open Movers: Wix Gains on Activist Stake, Take-Two Falls on GTA6 Hack
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
AutoZone (AZO) PT Raised to $2,450 at Jefferies Following Earnings
September 20, 2022 7:47 AM EDTJefferies analyst Bret Jordan raised the price target on AutoZone (NYSE: AZO) to $2,450.00 (from $2,350.00) while maintaining a Buy rating.
The analyst commented, "AZO's Q4'22 comp & EPS of 6.2% & $40.51 beat our ests. (+5.0% & $38.52) and cons. (+3.4% & $38.51) as DIFM was +22.0% y/y while DIY grew 1.1% despite lapping... More
Activist Involvement in Wix.com (WIX) Can Unlock 'Meaningful Value'
September 19, 2022 10:42 AM EDT(Updated - September 19, 2022 10:45 AM EDT)
Shares of Wix.com (NASDAQ: WIX) gained 10% early Monday after activist hedge fund Starboard Value disclosed a 9% stake in the company Friday afternoon and, according to reports from Reuters, spoke to the Israel-based website building platform about improving operations.
Starboard is said to support the company's plans to become profitable and believes it can improve its margins and grow further.... More
Wedbush Stays Sidelined on bluebird bio (BLUE) But Does Sees 'some short-term benefits' for the Company Following Skysona News
September 19, 2022 9:28 AM EDTWedbush analyst David Nierengarten reiterated a Neutral rating and $9.00 price target on bluebird bio (NASDAQ: BLUE).
The analyst comments "While we believe that the approval of SKYSONA is a win for patients suffering from CALD, we see short-term benefits for BLUE. With... More
